PATHFAST™ Presepsin is a chemiluminescent enzyme immunoassay for the quantitative measurement of presepsin (sCD14-ST) concentration in whole blood or plasma. PATHFAST™ Presepsin is used as an aid in the diagnosis and prognosis of sepsis, in the assessment of the degree of septic severity and to aid in the risk stratification of critically ill septic patients. PATHFAST™ Presepsin improves the diagnosis and prognosis of sepsis defining its level of severity. It is a valid indicator of risk stratification in septic patients. Due to the fast analysis within 15 minutes and the high prognostic value even at patient’s admission, PATHFAST™ Presepsin is useful in laboratories, emergency- and intensive care units and neonatal departments. An early diagnosis with an excellent prognostic performance and its ability to respond rapidly to the variety of clinical conditions make PATHFAST™ Presepsin the ideal tool for sepsis diagnosis and risk prognosis. Moreover, the diagnostic validity of Presepsin in neonatal sepsis has been evaluated in numerous clinical studies. Presepsin shows promising performance in diagnosing sepsis in neonates and prognosing severity of the disease.